
|Videos|October 17, 2015
Efficacy of Lanreotide for the Treatment of Neuroendocrine Tumors
Author(s)Martyn E. Caplin
Martyn E. Caplin, professor, lead clinician, Neuroendocrine Unit at the Royal Free Hospital, London, discusses the efficacy of lanreotide for the treatment of patients with neuroendocrine tumors, as shown in clinical trials such as the CLARINET study.
Advertisement
Martyn E. Caplin, professor, lead clinician, Neuroendocrine Unit at the Royal Free Hospital, London, discusses the efficacy of lanreotide for the treatment of patients with neuroendocrine tumors, as shown in clinical trials such as the CLARINET study.
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Phase 3 TROPION-Lung17 Trial Initiates TROP2-Directed Therapy in NSCLC
2
FDA Receives BLA for Ivonescimab in EGFR+ NSCLC
3
FDA Grants Orphan Drug Designation for Gotistobart in Squamous NSCLC
4
For a Second Time, FDA Denies Approval of Tab-Cel in EBV+ PTLD
5














































